Rising Neuroendocrine Tumors Fuel Treatment Market Growth Driving Market Acceleration in the Neuroendocrine Tumor Treatment Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Neuroendocrine Tumor Treatment Market Size By 2025?
The industry for treating neuroendocrine tumors has witnessed substantial growth in the previous years. The market size is projected to escalate from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The growth observed during the historic period is largely attributed to factors such as clinical knowledge and research, increased awareness and education, specialized medical professionalism, progress in radiation therapy, and the provision of supportive care services.

How Big Is the Neuroendocrine Tumor Treatment Market Size Expected to Grow by 2029?
The market size for neuroendocrine tumor treatments is predicted to experience substantial growth in the coming years, reaching a value of $3.6 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%. This projected growth over the forecast period can be credited to developments in precision medicine, innovations in immunotherapy, the advent of minimally invasive procedures, escalating incidence rates, and the introduction of telemedicine and remote care. Key trends during this period encompass improvements in diagnostic technologies, progress in peptide receptor radionuclide therapy (PRRT), the application of nanotechnology in drug delivery, the rise of emerging radiopharmaceuticals, and the increasing focus on cross-disciplinary collaboration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Which Key Market Drivers Powering Neuroendocrine Tumor Treatment Market Expansion and Growth?
The increasing number of cases of neuroendocrine tumors is predicted to boost the neuroendocrine tumor treatment market's expansion. These rare tumors, known as neuroendocrine tumors (NETs), start from neuroendocrine cells. The treatment of the neuroendocrine tumor is critical for the cure and is utilized to manage symptoms, regulate tumor growth, and employ radiation therapy to eliminate tumor cells. As an illustration, in March 2023, the American Society of Clinical Oncology (ASCO), a professional organization based in the US, reported that over 12,000 individuals in the US are diagnosed with neuroendocrine tumors annually, and around 171,000 people were living with this diagnosis in 2023. Additionally, in August 2022, Cancer Australia, an agency dedicated to cancer control in Australia, revealed that 5,437 individuals were diagnosed with neuroendocrine tumors in 2022, accounting for 3.4% of all new diagnoses in 2022. As a result, the increasing prevalence of neuroendocrine tumors fuels the expansion of the neuroendocrine tumor treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12248&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Neuroendocrine Tumor Treatment Market?
A primary trend escalating in prominence in the neuroendocrine tumor treatment market is clinical drug development. Major players in the market are focusing on creating innovative therapies to maintain their relevancy. As an example, Viewpoint Molecular Targeting, Inc., a pharmaceutical firm based in the US, reported in October 2022 that their drug in development, [212Pb] VMT-a-NET, received fast-track designation from the U.S. Food and Drug Administration (FDA), a federal agency of the US. This drug is being developed to treat patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs) and is a targeted alpha-particle therapy (TAT) intended to destroy cancer cells that selectively express somatostatin receptors. The fast-track designation is awarded by FDA to speed up the development and review process of drugs like [212Pb] VMT-a-NET, intended to treat NETs, that demonstrate potential for significantly enhancing the safety or efficacy of treatment for serious conditions.

What Are the Emerging Segments in the Neuroendocrine Tumor Treatment Market?
The neuroendocrine tumor treatment market covered in this report is segmented -

1) By Product: Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others Products
2) By Indication: Lungs, Pancreas, Gastrointestinal, Others Indications
3) By End-Users: Hospitals, Oncology Centers, Other End-Users

Subsegments:
1) By Somatostatin Analogs (SSAs): Octreotide, Lanreotide
2) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Peptide Receptor Radionuclide Therapy (PRRT)
3) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
4) By Other Products: Immunotherapy, Supportive Care Medications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12248&type=smp

Who Are the Global Leaders in the Neuroendocrine Tumor Treatment Market?
Major companies operating in the neuroendocrine tumor treatment market include Pfizer Inc., F Hoffmann-La Roche AG, Abbvie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Tarveda Therapeutics, GlycoMira Therapeutics Inc, AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., Chiasma Inc.

Which are the Top Profitable Regional Markets for the Neuroendocrine Tumor Treatment Industry?
North America was the largest region in the neuroendocrine tumor treatment market in 2024. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12248

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.